Table 1 Therapeutic response according to mRECIST criteria
Response | mRECIST for HCC |
|---|---|
Complete response (CR) | Disappearance of intratumoral arterial enhancement in target lesions |
Partial response (PR) | ≥ 30% decrease in the diameter of viable component measured in the arterial phase of the study |
Stable disease (SD) | Cases not fulfilling the criteria of partial response or progressive disease |
Progressive disease (PD) | Increase ≥ 20% in the diameters of the enhancing component |